Novartis Canada got a thumbs up from INESSS to help pay for Kisqali for breast cancer patients.

NVS · Novartis

The AI's read

This step could help more eligible patients get Kisqali through public coverage and help Novartis reach more patients. The trial result helps explain the recommendation. An earlier assessment limited who could qualify, and public payers still need to act, so broader coverage is not assured.